View More View Less
  • 1 Dél-pesti Centrumkórház, 1097 Budapest, Albert Flórián utca 5–7.
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $96.00

Absztrakt:

A myeloma multiplex első vonalbeli kezelése Magyarországon érdemben nem változott az elmúlt évizedben, alapját bortezomibbázisú tripletek és az arra alkalmasaknál nagy dózisú kemoterápiát követő autológ őssejtátültetés képezi.

Közleményünkben a myeloma multiplex első vonalbeli kezelésének legújabb fejleményeit foglaljuk össze az ASH (American Society of Hematology) és az EHA (European Hematology Association) kongresszusain bejelentetett eredmények ismertetésével.

Bár a smouldering myeloma (SMM) jelenleg nem kezelési indikáció, a nagy rizikójú SMM korai experimentális kezelési eredményei ígéretesek. Az újonnan diagnosztizált, transzplantációjelölt betegek első vonalbeli daratumumab- és/vagy carfilzomibbázisú indukciós kezelései kiemelkedően hatásosak, nem befolyásolják az őssejtgyűjtést, és növelik az autológ őssejtátültetéssel végzett konszolidációs terápia hatékonyságát.

A bizonyítottan hatékony lenalidomidfenntartó kezelésre nem jelölt betegek számára az ixazomibfenntartó kezelés már evidencián alapulhat. Nem transzplantábilis myelomás betegeink számára az első vonalbeli daratumumabbázisú kezelés több kombinációban is mély és tartós választ biztosíthat. Esendő betegeink lenalidomid-dexamethason első vonalbeli kezeléséből eredményes indukciót követően a szteroid káros következmények nélkül elhagyható, az elért eredményt a lenalidomid monoterápia fenntarthatja.

  • 1

    Liu C, Ghobrial I, Bustoros M, et al. Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. Blood 2018; 132: 154.

  • 2

    Bustoros M, Liu C, Reyes K, et al. Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. Blood 2018; 132: 804.

  • 3

    Jackson G, Davies F, Pawlyn C, et al. A quadruplet regimen comprising carfilzomib, cyclophosphamide, lenalidomide, dexamethasone (KCRD) vs an immunomodulatory agent containing triplet (CTD/CRD) induction therapy prior to autologous stem cell transplant: Results of the Myeloma XI Study. Blood 2018; 132: 302.

  • 4

    Gay F, Cerrato C, Scalabrini D, et al. Carfilzomib-lenalidomide-dexamethasone (KRd) induction-autologous transplant (ASCT)-Krd consolidation vs KRd 12 cycles vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction-ASCT-KCd consolidation: Analysis of the randomized forte trial in newly diagnosed multiple myeloma (NDMM). Blood 2018; 132: 121.

  • 5

    Gay F, Cerrato C, Scalabrini D, et al. Carfilzomib-lenalidomide-dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma (FORTE trial): Efficacy according to risk status. HemaSphere 2019, 3: 390–391.

  • 6

    Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375 (8): 754–766.

  • 7

    Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375 (14): 1319–1331.

  • 8

    Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 2017; 130 (8): 974–981.

  • 9

    Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018; 378 (6): 518–528.

  • 10

    Voorhees P, Rodriguez C, Reeves B, et al. Efficacy and updated safety analysis of a safety run-in cohort from griffin, a phase 2 randomized study of daratumumab (Dara), bortezomib (V), lenalidomide (R), and dexamethasone (D; Dara‐Vrd) vs. Vrd in patients (Pts) with newly diagnosed (ND) multiple myeloma (MM) eligible for high‐dose therapy (HDT) and autologous stem cell transplantation (ASCT). Blood 2018; 132: 151.

  • 11

    Moreau P, Attal M, Hulin C et al. Phase 3 randomized study of daratumumab + bortezomin/thalidomide/dexamethasone (D-VTD) versus VTD in transplant-eligible newly diagnosed multiple myeloma: Part 1 CASSIOPEIA results. HemaSphere 2019: 3: 24–25.

  • 12

    Dachs L, Oriol A, Teruel A, et al. VTD (bortezomib/thalidomide/dexamethasone) as pretransplant induction therapy for multiple myeloma: Definitive results of a randomized phase 3 Pethema/GEM Study. Blood 2018; 132: 126.

  • 13

    Cavo M, Goldschmidt H, Rosinol R, et al. Double vs single autologous stem cell transplantation for newly diagnosed multiple myeloma: Long-term follow-up (10-years) analysis of randomized phase 3 studies. Blood 2018; 132: 124.

  • 14

    Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376 (9758): 2075– 2085.

  • 15

    Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012; 120 (8): 1589–1596.

  • 16

    Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol. 2012; 30 (24): 2946–2955.

  • 17

    Tacchetti P, Dozza D, Di Raimondo F, et al. Bortezomib-thalidomide- dexamethasone versus thalidomide-dexamethasone before and after double autologous stem cell transplantation for newly diagnosed multiple myeloma: Final analysis of phase 3 Gimema-MMY-3006 Study and prognostic score for survival outcomes. Blood 2018; 132: 125.

  • 18

    Shi X, Yan L, Shang J, et al. Tandom autologous transplantation and combined infusion of CD19 and BCMA-specific chimeric antigen receptor T cells for high risk MM: Initial safety and efficacy report from a clinical pilot study. Blood 2018; 132: 1009.

  • 19

    Dimopoulos M, Gay F, Schjesvold F, et al. Maintenance therapy with the oral proteasome inhibitor (PI) ixazomib significantly prolongs progression-free survival (PFS) following autologous stem cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. Blood 2018; 132: 301.

  • 20

    Vij R, Nathwani N, Martin III T, et al. Ixazomib-lenalidomide-dexamethasone (IRd) consolidation following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: A large multi-center phase II trial. Blood 2018; 132: 123.

  • 21

    Skarbnik A, Donato M, Korngold R, et al. Safety and efficacy data for combined checkpoint inhibition with ipilimumab (Ipi) and nivolumab (Nivo) as consolidation following autologous stem cell transplantation (ASCT) for high-risk hematological malignancies – CPIT-001 Trial. Blood 2018; 132: 256.

  • 22

    Bygrave C, Pawlyn C, Davies F, et al. Progression free survival below 12 months following stem cell transplant is a hallmark of high-risk myeloma which is associated with inferior overall survival – Data from the UKMRC Myeloma XI Trial. Blood 2018; 132: 122.

  • 23

    Takamatsu H, Takezako N, Wee R, et al. Comparison of minimal residual disease detection in autografts of patients with multiple myeloma between 8-color multiparameter flow cytometry (EuroFlow) and next-generation sequencing. Blood 2018; 132: 258.

  • 24

    Takamatsu H, Takezako N, Zheng J, et al. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation. Ann Oncol. 2017; 28 (10): 2503–2510.

  • 25

    Zamagni E, Nanni C, Dozza L, et al. Standardization of 18F-FDG PET/CT according to deauville criteria for mrd evaluation in newly diagnosed transplant eligible multiple myeloma patients: Joined analysis of two prospective randomized phase III trials. Blood 2018; 132: 257.

  • 26

    Facon T, Kumar S, Plesner T, et al. Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA). Blood 2018; 132: LBA-2.

  • 27

    Dimopoulos M, Mateos M, Cavo M, et al. One-year update of a phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in patients (Pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): Alcyone. Blood 2018; 132: 156.

  • 28

    Ocio E, Otero P, Bringhen S, et al. Preliminary results from a phase I study of isatuximab (ISA) in combination with bortezomib, lenalidomide, dexamethasone (VRd), and in patients with newly diagnosed multiple myeloma (NDMM) non-eligible for transplant. Blood 2018; 132: 595.

  • 29

    Stege C, Nasserinejad K, Levin M, et al. Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) in unfit and frail newly diagnosed multiple myeloma (NDMM) patients; first interim safety analysis of the phase II HOVON 143 Study. Blood 2018; 132: 596.

  • 30

    Zweegman S, Schjesvold F, van der Holt B, et al. Ixazomib-thalidomide-low dose dexamethasone (ITd) induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized Phase II HOVON-126/Nmsg 21#13 Trial. Blood 2018; 132: 800.

  • 31

    Larocca A, Salvini M, De Paoli L, et al. Efficacy and feasibility of dose/schedule- adjusted Rd-R vs. continuous Rd in elderly and intermediate-fit newly diagnosed multiple myeloma (NDMM) patients: RV-MM-PI-0752 Phase III Randomized Study. Blood 2018; 132: 305.

  • 32

    Weisel K, Ramasamy K, Owen M et al. Relative efficacy of approved and recently introduced treatments for newly diagnosed multiple myeloma: A network meta-analysis. HemaSphere 2019; 3: 636.

  • 33

    Landgren O, Siegel D, Auclair D, et al. Carfilzomib-lenalidomide-dexamethasone versus bortezomib-lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma: Results from the prospective, longitudinal, observational commpass study. Blood 2018; 132: 799.

  • 34

    Kumar S, Kapoor P, Laplant B, et al. Phase 2 trial of ixazomib, lenalidomide, dexamethasone and daratumumab in patients with newly diagnosed multiple myeloma. Blood 2018; 132: 304.

  • 35

    Yimer H, Melear J, Faber E, et al. Lyra: A phase 2 study of daratumumab (Dara) plus cyclophosphamide, bortezomib, and dexamethasone (Cybord) in newly diagnosed and relapsed patients (Pts) with multiple myeloma (MM). Blood 2018; 132: 152.